Highlights Iterum Therapeutics plc

Equities

ITRM

IE000TTOOBX0

Market Closed - Nasdaq Other stock markets 21:00:00 13/05/2024 BST			5-day change	1st Jan Change
1.52 ^USD	-1.94%		-4.40%	-22.84%

05-10	Iterum Therapeutics plc Announces Executive Changes	CI
04-29	Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem	04-29	CI
Iterum Therapeutics plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-28	CI
Iterum Therapeutics Says UTI Drug Trial Met Primary Endpoint	01-30	DJ
Iterum Therapeutics plc Announces Positive Topline Results from Its Phase 3 Reassure Clinical Trial of Oral Sulopenem in Un Complicated Urinary Tract Infections	01-30	CI
Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Iterum Therapeutics plc Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	24/10/23	CI
Iterum Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Iterum Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
ITERUM THERAPEUTICS PLC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	16/03/23	AQ
ITERUM THERAPEUTICS PLC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	10/11/22	AQ
Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
Earnings Flash (ITRM) ITERUM THERAPEUTICS Reports Q3 Loss $-0.43, vs. Street Est of $-0.92	10/11/22	MT
Iterum Therapeutics Reports Dosing First Patient in Late-Stage Urinary Tract Infections Trial	20/10/22	MT
Iterum Announces First Patient Dosed in Reassure, A Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	20/10/22	CI
Iterum Therapeutics plc Announces Issuance of Allowance for A U.S. Patent Covering Oral Sulopenem	19/09/22	CI
ITERUM THERAPEUTICS PLC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	12/08/22	AQ
Iterum Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22	CI
Earnings Flash (ITRM) ITERUM THERAPEUTICS Reports Q2 Loss $-0.03	12/08/22	MT
Iterum Therapeutics Lands Special Protocol Assessment Agreement with FDA; Shares Rise	11/07/22	MT
Iterum Therapeutics plc Announces Special Protocol Assessment Agreement with the FDA	11/07/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Iterum Therapeutics plc

Equities

ITRM

IE000TTOOBX0

Highlights

Filters